We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.1%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.83B
AUM Growth
-$798M
Cap. Flow
-$482M
Cap. Flow %
-17.04%
Top 10 Hldgs %
54.55%
Holding
115
New
16
Increased
15
Reduced
28
Closed
28

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$101M
2
BBNX
Beta Bionics
BBNX
+$29.7M
3
INSM icon
Insmed
INSM
+$27.9M
4
DYN icon
Dyne Therapeutics
DYN
+$25.3M
5
SLDB icon
Solid Biosciences
SLDB
+$21.4M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$80.9M
2
NUVL
Nuvalent
NUVL
+$77.1M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$62.8M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$62.6M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$54.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRV icon
51
Acrivon Therapeutics
ACRV
$61.2M
$10.9M 0.38%
5,360,858
– –
NAUT icon
52
Nautilus Biotechnolgy
NAUT
$131M
$10.8M 0.38%
12,594,211
– –
AQST icon
53
Aquestive Therapeutics
AQST
$452M
$10.8M 0.38%
+3,727,208
New +$11.3M
CTNM
54
Contineum Therapeutics
CTNM
$539M
$10.1M 0.36%
1,441,249
– –
CRGX
55
DELISTED
CARGO Therapeutics
CRGX
$9.89M 0.35%
2,431,085
-1,251,919
-34% -$8.38M
OM icon
56
Outset Medical
OM
$85.5M
$9.22M 0.33%
+833,333
New +$9.94M
VRDN icon
57
Viridian Therapeutics
VRDN
$2.19B
$8.89M 0.31%
659,662
-826,846
-56% -$14.1M
EYPT icon
58
EyePoint Inc
EYPT
$999M
$8.33M 0.29%
1,537,274
– –
ADGM
59
Adagio Medical Holdings
ADGM
$9.36M
$7.9M 0.28%
9,812,419
– –
AVR
60
Anteris Technologies
AVR
$770M
$7.79M 0.28%
2,140,000
– –
IRON icon
61
Disc Medicine
IRON
$2.82B
$7.45M 0.26%
+150,000
New +$8.34M
ADPT icon
62
Adaptive Biotechnologies
ADPT
$3.61B
$6.92M 0.24%
+930,972
New +$7.16M
OCUL icon
63
Ocular Therapeutix
OCUL
$1.83B
$6.71M 0.24%
915,775
-162,720
-15% -$1.25M
DCTH icon
64
Delcath Systems
DCTH
$399M
$5.89M 0.21%
462,422
+412,422
+825% +$5.85M
RAPT
65
DELISTED
RAPT Therapeutics
RAPT
$5.39M 0.19%
552,368
-182,632
-25% -$1.8M
KMTS
66
Kestra Medical Technologies
KMTS
$1.33B
$4.98M 0.18%
+200,000
New +$4.6M
BBOT
67
BridgeBio Oncology
BBOT
$658M
$4.5M 0.16%
398,000
-102,000
-20% -$1.1M
OKUR
68
OnKure Therapeutics
OKUR
$160M
$4.32M 0.15%
1,004,439
– –
IRD
69
Opus Genetics
IRD
$286M
$4.25M 0.15%
+4,325,000
New +$4.83M
AVTX icon
70
Avalo Therapeutics
AVTX
$1.01B
$4.17M 0.15%
+520,000
New +$3.94M
NRIX icon
71
Nurix Therapeutics
NRIX
$2.45B
$3.53M 0.12%
297,553
-33,061
-10% -$553K
MREO
72
Mereo BioPharma
MREO
$49.8M
$1.97M 0.07%
876,961
-208,551
-19% -$590K
LYRA
73
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.61M 0.06%
255,151
– –
KALA icon
74
KALA BIO
KALA
$12.9M
$1.59M 0.06%
+5,552
New +$2.1M
LONA
75
LeonaBio Inc
LONA
$65.3M
$1.54M 0.05%
540,296
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Perceptive Advisors held 115 positions worth $2.83B, down 22% from $3.63B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors withdrew a net $482M in Q1 2025, closing 28 positions and reducing 28 holdings. Its most notable exit was Procept Biorobotics, an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Beta Bionics worth $19.5M.

  • Perceptive Advisors's largest Q1 2025 buy was Beta Bionics: 1,593,608 shares worth $19.5M.
  • Perceptive Advisors added most to Edgewise Therapeutics in Q1 2025, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2025 reduction was Vaxcyte, cutting an estimated $80.9M.
  • Perceptive Advisors fully exited Procept Biorobotics in Q1 2025, selling an estimated $23.4M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $2.83B portfolio in Q1 2025.
  • Perceptive Advisors opened 16 new positions and closed 28 in Q1 2025.
  • Perceptive Advisors's portfolio value fell 22% quarter-over-quarter to $2.83B.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.